Product Description
Boehringer Ingelheim is developing BI-764532 as a treatment for Patients With Small Cell Lung Carcinoma and Other Neoplasms. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04429087)
Mechanisms of Action: DLL3 Inhibitor, CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Large Cell Carcinoma|Neuroendocrine CarcinomaFast Track - Lung Cancer|Small Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Bulgaria, China, France, Germany, Italy, Japan, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 15
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Large Cell Carcinoma|Neuroendocrine Carcinoma|Small Cell Lung Cancer
Phase 1: Glioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05916313 |
U1111-1290-7234 | P1 |
Active, not recruiting |
Glioma |
2026-02-23 |
50% |
2025-12-05 |
Primary Endpoints|Treatments |
2023-504247-13-00 |
1438-0005 | P2 |
Recruiting |
Large Cell Carcinoma|Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2025-07-03 |
12% |
2025-05-02 |
Treatments |
NCT05963867 |
NCT05963867 | P1 |
Recruiting |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2026-05-18 |
50% |
2025-10-29 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
NCT06077500 |
DAREONáµá´¹-8 | P1 |
Active, not recruiting |
Small Cell Lung Cancer |
2026-09-01 |
50% |
2025-12-20 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT05990738 |
DAREONTM-9 | P1 |
Recruiting |
Small Cell Lung Cancer |
2026-06-30 |
50% |
2025-04-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
jRCT2031230615 |
jRCT2031230615 | P1 |
Not yet recruiting |
Small Cell Lung Cancer |
2026-06-30 |
|||
jRCT2031230511 |
jRCT2031230511 | P1 |
Not yet recruiting |
Neuroendocrine Carcinoma |
2025-10-01 |
|||
NCT05879978 |
NCT05879978 | P1 |
Active, not recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2025-06-11 |
50% |
2025-10-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
JapicCTI-205404 |
JapicCTI-205404 | P1 |
Planned |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2024-08-15 |
|||
jRCT2031220716 |
jRCT2031220716 | P1 |
Recruiting |
Small Cell Lung Cancer|Neuroendocrine Carcinoma |
2024-05-30 |
|||
NCT05882058 |
DAREONâ¢-5 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Small Cell Lung Cancer |
2027-01-29 |
12% |
2025-12-11 |
Primary Completion Date|Primary Endpoints |
jRCT2041230084 |
jRCT2041230084 | P2 |
Not yet recruiting |
Small Cell Lung Cancer |
2025-07-03 |
|||
CTR20232621 |
CTR20232621 | P2 |
Active, not recruiting |
Small Cell Lung Cancer |
None |
2025-07-27 |
Treatments |
|
NCT06132113 |
DAREONâ¢-7 | P1 |
Recruiting |
Neuroendocrine Carcinoma |
2027-02-09 |
50% |
2025-12-18 |
Primary Endpoints |
NCT04429087 |
NCT04429087 | P1 |
Recruiting |
Small Cell Lung Cancer |
2026-09-01 |
50% |
2025-10-16 |
Primary Completion Date|Primary Endpoints |